Regeneron Pharmaceuticals, Inc. (BVMF:REGN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 436.34B +34.0% |
| Revenue (ttm) | 80.48B +9.3% |
| Net Income | 22.43B -2.9% |
| EPS | 3.62 +1.9% |
| Shares Out | n/a |
| PE Ratio | 20.06 |
| Forward PE | 11.46 |
| Dividend | 0.21 (0.29%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 215 |
| Open | 72.65 |
| Previous Close | 72.24 |
| Day's Range | 72.65 - 72.75 |
| 52-Week Range | 50.00 - 73.33 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron price target raised to $922 from $875 at Canaccord
Canaccord analyst John Newman raised the firm’s price target on Regeneron (REGN) to $922 from $875 and keeps a Buy rating on the shares. The firm updated its model ahead…
Regeneron announces longer-term data for Phase 3 C-POST trial of Libtayo
As previously reported on October 25, Regeneron (REGN) Pharmaceuticals announced longer-term data reflecting nearly four years of follow-up from the Phase 3 C-POST trial evaluating PD-1 inhibitor Libt...
Regeneron extends US agreement for additional supply of Ebola treatment
Regeneron said on Monday it extended its agreement with a US health authority to provide additional supply of its Ebola treatment, amid a growing outbreak in Africa.
Regeneron extends Inmazeb agreement with BARDA for Ebola preparedness
Regeneron (REGN) announced that it has extended its agreement with the Biomedical Advanced Research and Development Authority, or BARDA, part of the Administration for Strategic Preparedness and Respo...
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placeb...
Regeneron price target raised to $980 from $960 at TD Cowen
TD Cowen raised the firm’s price target on Regeneron (REGN) to $980 from $960 and keeps a Buy rating on the shares. The fim updated its model ahead of Q3…
Regeneron price target raised to $865 from $854 at Piper Sandler
Piper Sandler raised the firm’s price target on Regeneron (REGN) to $865 from $854 and keeps an Overweight rating on the shares. Ahead of Q3 2026 earnings for the group,…
Regeneron gets CHMP opinion recommending Libtayo alternative dosing schedule
Regeneron (REGN) announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the approval of an alternative dos...
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
Regeneron assumed with Buy from Neutral at UBS
UBS upgraded Regeneron (REGN) to Buy from Neutral with a price target of $978, up from $660, after assuming coverage of the name. The shares at current levels are not…
Regeneron announces results from Phase 3 OPTIMA trial of Pasatru
Regeneron (REGN) Pharmaceuticals announced 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru in adults with fibrodysplasia ossificans progressiva. These longer-term findings for Pasatru...
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with ...
Regeneron price target raised to $908 from $891 at BofA
BofA raised the firm’s price target on Regeneron (REGN) to $908 from $891 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q3 report.
Regeneron price target raised to $810 from $737 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron (REGN) to $810 from $737 and keeps a Sector Perform rating on the shares as part of a…
Regeneron price target raised to $780 from $772 at Truist
Truist raised the firm’s price target on Regeneron (REGN) to $780 from $772 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Regeneron price target raised to $779 from $758 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $779 from $758 and keeps an Equal Weight rating on the shares. The firm adjusted its models for its…
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Regeneron price target raised to $950 from $900 at JPMorgan
JPMorgan raised the firm’s price target on Regeneron (REGN) to $950 from $900 and keeps an Overweight rating on the shares ahead of the Q3 report. The firm expects a…
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Regeneron price target raised to $930 from $870 at Jefferies
Jefferies raised the firm’s price target on Regeneron (REGN) to $930 from $870 and keeps a Buy rating on the shares. The company’s expanded collaboration with Sanofi (SNY) on four…
Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (SNY) enhances both companies’ ability to capitalize…
Regeneron says ubamatamab shows high rate of durable responses in initial study
Regeneron (REGN) Pharmaceuticals announced the first results for the investigational ubamatamab in patients with low-grade serous ovarian cancer. The data are from an ongoing Phase 1/2 trial in recurr...
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition...